| Drug Name: | Quinidine (56-54-2) |
|---|---|
| PubChem ID: | 24096961 |
| SMILES: | COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@@H]3CC4CCN3CC4C=C)O |
| InchiKey: | LOUPRKONTZGTKE-CLONCEMUSA-N |
| Therapeutic Category: | Adrenergic Agents, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Anti-Arrhythmia Agents, Anti-Infective Agents, Antimalarials, Antiparasitic Agents, Antiprotozoal Agents, Cardiovascular Agents, Cholinergic Agents, Cholinergic Antagonists, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Membrane Transport Modulators, Muscarinic Antagonists, Neurotransmitter Agents, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers |
| Molecular Weight (dalton) | : | 324.424 |
| LogP | : | 3.1732 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 4 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 45.59 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Procainamide (51-06-9) | Prolongs The Qt Interval | Additive | It has been suggested that the quinidine interferes with one or more of the renal pathways by which procainamide is cleared from the body | Increased procainamide plasma concentrations caused by quinidine: a new drug interaction |
| Acetylsalicylic acid (50-78-2) | Gastrointestinal Bleeding | Additive | The underlying mechanism is not totally understood both of which can reduce platelet aggregation, although with quinidine this antiplatelet effect usually only occurs as the result of a hypersensitivity reaction. | Cumulative effects of quinidine and aspirin on bleeding time and platelet alpha 2-adrenoceptors: potential mechanism of bleeding diathesis in patients receiving this combination |
| Amiloride (2609-46-3) | Opposed Antiarrhythmic Activity Of Quinidine | Antagonistic | Not understood. The combination of quinidine and amiloride increased the QRS interval, but did not prolong the QT interval more than quinidine alone. | Amiloride-quinidine interaction: adverse outcomes |
| Amiodarone (1951-25-3) | Torsade De Pointes | Additive | The mechanism behind the pharmacokinetic interaction is not understood. The QT prolonging effects of the two drugs would be expected to be additive. | Dangerous interaction between amiodarone and quinidine |
| Erythromycin (114-07-8) | Torsade De Pointes | Additive | Not fully understood, but erythromycin inhibits the metabolism of quinidine, possibly by inhibition of the cytochrome P450 isoenzyme CYP3A4, thereby reducing its clearance from the body and increasing its effects. Quinidine and erythromycin may have additive effects on the QT interval in addition to the pharmacokinetic interaction. | Possible inhibition of hepatic metabolism of quinidine by erythromycin |
| Lidocaine (137-58-6) | Sinoatrial Arrest | Antagonistic | Not fully understood | Sinoatrial arrest due to lidocaine in a patient receiving quinidine |
| Moxifloxacin (151096-09-2) | Torsade De Pointes | Additive | Not fully understood | The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine |
| Phenytoin (57-41-0) | Loss Of Arrhythmia Control | Antagonistic | The evidence suggests that phenytoin, primidone or phenobarbital (all known enzyme-inducers) increase the hepatic metabolism of quinidine and thereby reduce its levels | Interaction of quinidine with anticonvulsant drugs |
| Ranitidine (66357-35-5) | Arrhythmia | Antagonistic | It was originally suggested that the ranitidine inhibits the metabolism of the quinidine by the liver so that it is cleared more slowly. | Quinidine-ranitidine adverse reaction |
| verapamil (52-53-9) | Hypotension | Antagonistic | The interaction with verapamil is probably due to an inhibitory effect of verapamil on the metabolism of quinidine (inhibition of cytochrome P450 isoenzyme CYP3A). The marked hypotension observed may be related to the antagonistic effects of the two drugs on catecholamine-induced alpha-receptor induced vasoconstriction | The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine |
| Codeine (76-57-3) | Analgesic Effect Decreased | Antagonistic | The conversion of codeine to its active analgesic metabolite in the body depends upon the activity of the cytochrome P450 isoenzyme CYP2D6 in the liver. This isoenzyme is inhibited by quinidine, these conversions largely fail to occur and the analgesic effects are reduced or lost | The effect of quinidine on the analgesic effect of codeine |
This panel provides drug-protein interaction and their ADRs along with references
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|---|---|
| Grapefruit Juice | Torsade De Pointes | Grapefruit-medication interactions: forbidden fruit or avoidable consequences? |
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category